microfluidics
Angle, BioView Partner to Develop Quantitative HER2 Assay Using Circulating Tumor Cells
The companies said recent developments in HER2-targeted therapies have created new commercial opportunities for a blood-based test.
ScreenIn3D Platform Relies on Microfluidics, 3D Modeling to Monitor Cancer Treatment Efficacy
Premium
The firm's most recent research investigates how the platform could be applied to CAR-T therapy for solid tumors.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.